Live Breaking News & Updates on மருந்து மறுபயன்பாடு|Page 2

Stay updated with breaking news from மருந்து மறுபயன்பாடு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Changes in how cholesterol breaks down in the body may accelerate progression of dementia


 E-Mail
IMAGE: Investigators with the National Institute on Aging, part of the National Institutes of Health, are searching for drug candidates that may correct the brain s metabolic abnormalities, such as cholesterol breakdown.
view more 
Credit: Dr. Vijay R. Varma
The blood-brain barrier is impermeable to cholesterol, yet high blood cholesterol is associated with increased risk of Alzheimer s disease and vascular dementia. However, the underlying mechanisms mediating this relationship are poorly understood. A study published in the open-access journal
PLOS Medicine by Vijay Varma and colleagues at the National Institute on Aging, part of the National Institutes of Health, in Baltimore, Maryland, suggests that disturbances in the conversion of cholesterol to bile acids (called cholesterol catabolism) may play a role in the development of dementia. ....

National Institutes Of Health , United States , United Kingdom , Lilliana Posey , Madhav Thambisetty , Vijay Varma , National Cancer Institute , Alzheimer Disease Neuroimaging Initiative , Consortium Molecular Mechanisms Of The Vascular Etiology , National Institute On , Research Article , Medicines Partnership , Laboratory Of Behavioral Neuroscience , National Institute On Aging , National Institute , National Institutes , Baltimore Longitudinal Study , Disease Neuroimaging Initiative , Translational Neuroscience , Drug Repurposing , Effective Alzheimer , Accelerated Medicines Partnership , Target Discovery , Preclinical Validation Project , Molecular Mechanisms , Vascular Etiology ,

Global To Help The Drug Repurposing Market Stand In A Good Stead – KSU


atulpmrApril 24, 2021
1
The Drug Repurposing Market report by Persistence Market Research is focusing on the fact that healthcare providers are into collection of socioeconomic information of the patients, so that tracking at any point of time is possible. This on-the-go monitoring is amongst the ongoing trends in the healthcare industry.
Drug repurposing or re-profiling has been the hallmark to bring strong business growth and the trend is being followed by majority of the pharmaceutical and biopharmaceutical companies. Among all biologics approved in the U.S. during 2007-2009, 30-40% of them were the drugs repurposed or repositioned. National Institute of Health (NIH), U.S. Department of Health defines drug repurposing as discovering new uses for approved drugs to provide the quickest possible transition from bench to bedside. Drug repurposing opens up various opportunities to answer current unmet medical needs to come up with cost-effective solutions to expensive ....

New York , United States , Asia Pacific , National Center , Allergan Plc , National Institute Of Health , Us Department Of Health , Translational Sciences , Persistence Market Research , Astellas Pharma Inc , Pfizer Inc , Abbvie Inc , Drug Repurposing , Latin America , Middle East , North America , Advancing Translational , Extensive Coverage , Persistence Market Research Healthcare , Market Research , New York City , States Canada Toll Free , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ஆசியா பெஸிஃபிக் , தேசிய மையம் ,

Researchers use AI to identify drugs that could be repurposed for Alzheimer's


Researchers use AI to identify drugs that could be repurposed for Alzheimer’s
Eli Lilly s JAK inhibitor Olumiant identified as a potential treatment for repurposing
Researchers from Harvard Medical School and Massachussetts General Hospital have revealed which drugs could be potentially repurposed as possible treatments for Alzheimer’s disease using artificial intelligence (AI).
The research team developed an AI-based method that enabled them to screen US Food and Drug Administration (FDA) approved medications for their potential as repurposed Alzheimer’s treatments.
The study, published in
Nature Communications, used a framework called DRIAD (Drug Repurposing in Alzheimer’s Disease) which uses machine learning to measure what happens to human brain neural cells when treated with a drug. ....

Artem Sokolov , Eli Lilly Olumiant , Nature Communications , Laboratory Of Systems Pharmacology , Drug Administration , Harvard Medical School , Massachussetts General Hospital , Drug Repurposing , Systems Pharmacology , Harvard Medical , Eli Lilly , இயற்கை தகவல்தொடர்புகள் , ஆய்வகம் ஆஃப் அமைப்புகள் மருந்தியல் , ஹார்வர்ட் மருத்துவ பள்ளி , மாசசூசெட்ஸ் ஜநரல் மருத்துவமனை , மருந்து மறுபயன்பாடு , அமைப்புகள் மருந்தியல் , ஹார்வர்ட் மருத்துவ , எலி லில்லி ,